[go: up one dir, main page]

FR2917622B1 - Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale. - Google Patents

Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Info

Publication number
FR2917622B1
FR2917622B1 FR0755848A FR0755848A FR2917622B1 FR 2917622 B1 FR2917622 B1 FR 2917622B1 FR 0755848 A FR0755848 A FR 0755848A FR 0755848 A FR0755848 A FR 0755848A FR 2917622 B1 FR2917622 B1 FR 2917622B1
Authority
FR
France
Prior art keywords
treatment
atrial fibrillation
par1 antagonist
par1
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0755848A
Other languages
English (en)
Other versions
FR2917622A1 (fr
Inventor
Michel Perez
Grand Bruno Le
Robert Letienne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0755848A priority Critical patent/FR2917622B1/fr
Priority to TW097122521A priority patent/TW200908977A/zh
Priority to PA20088784901A priority patent/PA8784901A1/es
Priority to CL200801795A priority patent/CL2008001795A1/es
Priority to PCT/EP2008/057645 priority patent/WO2008155335A1/fr
Priority to ARP080102612A priority patent/AR067061A1/es
Publication of FR2917622A1 publication Critical patent/FR2917622A1/fr
Application granted granted Critical
Publication of FR2917622B1 publication Critical patent/FR2917622B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0755848A 2007-06-19 2007-06-19 Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale. Expired - Fee Related FR2917622B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR0755848A FR2917622B1 (fr) 2007-06-19 2007-06-19 Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.
TW097122521A TW200908977A (en) 2007-06-19 2008-06-17 Use of a PAR-1 antagonist for the treatment of atrial fibrillation
PA20088784901A PA8784901A1 (es) 2007-06-19 2008-06-17 Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial
CL200801795A CL2008001795A1 (es) 2007-06-19 2008-06-17 Uso de un antagonista par1 en el tratamiento de la fibrilacion atrial.
PCT/EP2008/057645 WO2008155335A1 (fr) 2007-06-19 2008-06-18 Antagonistes du récepteur 1 activé par une protéase destinés au traitement de la fibrillation atriale
ARP080102612A AR067061A1 (es) 2007-06-19 2008-06-19 Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0755848A FR2917622B1 (fr) 2007-06-19 2007-06-19 Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Publications (2)

Publication Number Publication Date
FR2917622A1 FR2917622A1 (fr) 2008-12-26
FR2917622B1 true FR2917622B1 (fr) 2009-10-23

Family

ID=38973629

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0755848A Expired - Fee Related FR2917622B1 (fr) 2007-06-19 2007-06-19 Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.

Country Status (6)

Country Link
AR (1) AR067061A1 (fr)
CL (1) CL2008001795A1 (fr)
FR (1) FR2917622B1 (fr)
PA (1) PA8784901A1 (fr)
TW (1) TW200908977A (fr)
WO (1) WO2008155335A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2902426B1 (fr) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa Derives de cinnamoyl-piperazine
FR2902427B1 (fr) * 2006-06-19 2008-08-22 Pierre Fabre Medicament Sa Derives de phenylpentadienoyle
CN104496879A (zh) * 2015-01-13 2015-04-08 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯氟代金刚烷结构的化合物和用途
CN104478782B (zh) * 2015-01-13 2016-03-16 佛山市赛维斯医药科技有限公司 一类含烷氧苯基和二烯氟代金刚烷结构的化合物和用途
CN104447485A (zh) * 2015-01-13 2015-03-25 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯金刚烷结构的化合物、其制备方法和用途
CN104478781A (zh) * 2015-01-13 2015-04-01 佛山市赛维斯医药科技有限公司 二烯金刚烷类化合物、其制备方法和用途
WO2017134200A1 (fr) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. Nouvelle composition pharmaceutique à base de vorapaxar et de métoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
KR102268589B1 (ko) * 2019-04-29 2021-06-24 사회복지법인 삼성생명공익재단 단백질분해효소 활성 수용체 매개 신호전달 경로의 활성을 이용한 세포외 소포의 고효율 생성능을 갖는 줄기세포의 선별방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61106564A (ja) * 1984-10-30 1986-05-24 Terumo Corp 不飽和脂肪酸アミド誘導体およびこれを含有する血小板凝集抑制剤
JPS61137866A (ja) * 1984-12-07 1986-06-25 Terumo Corp イミダゾ−ル誘導体およびこれを含有する血小板凝集抑制剤

Also Published As

Publication number Publication date
PA8784901A1 (es) 2009-01-23
TW200908977A (en) 2009-03-01
CL2008001795A1 (es) 2008-10-10
AR067061A1 (es) 2009-09-30
WO2008155335A1 (fr) 2008-12-24
FR2917622A1 (fr) 2008-12-26

Similar Documents

Publication Publication Date Title
FR20C1066I2 (fr) Pièges à gdf pour l'utilisation dans le traitment de l'anémie
FR2917622B1 (fr) Utilisation d'un antagoniste par1 dans le traitement de la fibrillation atriale.
EP2217697A4 (fr) Utilisation des antagonistes de lingo-4 dans le traitement d'états mettant en jeu une démyélination
BRPI0811871A2 (pt) Composições agroquímicas ácidas bioativas e uso das mesmas
EP2366785A4 (fr) Dérivé d'oligonucléotide, agent de marquage et utilisation de l'agent de marquage
JP2009039101A5 (fr)
EP2213313A4 (fr) Echafaudage d'élution médicale de trioxyde d'arsenic
EP2027849A4 (fr) Préparation à usage externe pour la peau
FR2920305B1 (fr) Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
EP2114377A4 (fr) Libération contrôlée d'agents actifs dans la peau
EP1824510A4 (fr) Utilisation de la flagelline dans l'immunotherapie de yersinia pestis
FR2920306B1 (fr) Utilisation cosmetique d'un lysat de bifidobacterieum species.
BRPI0816038A2 (pt) "composição de tratamento dos cabelos"
EP2217576A4 (fr) Composés benzodiazépinone utiles dans le traitement d'affections de la peau
BRPI0812766A2 (pt) 4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
FR2887450B1 (fr) Ingredient concentre pour le traitement et/ou la modification de surfaces, et son utilisation dans des compositions cosmetiques
DK3311810T3 (da) Anvendelse af sulcardin til behandling af atrieflimmer
DK3156057T3 (da) Delmopinol-belagt dyretyggeartikel til anvendelse til forebyggelsen eller behandlingen af halitosis
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
FR2905270B1 (fr) Utilisation de sucres en c7 dans la prevention et le traitement des mycoses
EP2123284A4 (fr) Agent prophylactique et/ou thérapeutique pour un infarctus cardiaque
EP2219594A4 (fr) Utilisation d'un inhibiteur de transglutaminase pour le traitement de la peau
DE602005010492D1 (de) EKG-Referenzwertberechnung
EP1908467A4 (fr) Agent thérapeutique dérivé de l'herpèsvirus contre la douleur
FI20041641L (fi) Sovitelma silmänpainemittarissa

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

ST Notification of lapse

Effective date: 20210206